Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
Date:5/10/2013

ients in a pivotal Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome and a Phase 2 clinical trial of telotristat etiprate in ulcerative colitis. Telotristat etiprate is an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.
  • LX1033: Lexicon continues to enroll patients in a Phase 2 clinical trial of LX1033 in patients with diarrhea-predominant IBS (IBS-d).  LX1033 is an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract to reduce serotonin production without impacting brain serotonin levels.
  • Financial ResultsRevenues:  Lexicon's revenues for the three months ended March 31, 2013 increased 20 percent to $0.4 million from $0.3 million for the corresponding period in 2012.  The increase for the three months ended March 31, 2013 was primarily attributable to higher revenues from Lexicon's alliance with Taconic Farms.

    Research and Development Expenses:  Research and development expenses for the three months ended March 31, 2013 decreased 12 percent to $20.3 million from $23.0 million for the corresponding period in 2012.  The decrease was primarily attributable to decreases in external manufacturing, clinical research and development costs, facility costs and personnel costs.

    Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was $1.3 million and $2.1 million for the three mon
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
    2. Lexicon to Report First Quarter Financial Results on May 10, 2013
    3. Lexicon To Present At The Needham Healthcare Conference
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
    5. Lexicon To Present At The BIO CEO & Investor Conference
    6. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    8. Lexicon to Provide Third Quarter 2012 Financial Results
    9. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    10. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    11. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
    (Date:8/29/2014)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... release its financial results for the fiscal 2014 fourth ... trading ends on Tuesday, September 9, 2014. ... p.m. U.S. EDT on Tuesday, September 9, 2014 (Wednesday, ... Company,s financial results, commercial partnerships, and future outlook.  The ...
    (Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
    Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
    ... Colo., Oct. 7 Waleed Danho, Ph.D., Distinguished Research ... 2009 recipient of the Meienhofer Award for excellence in ... RCCPS ( http://www.rochecolorado.com/PeptideSymp09/ ). Hosted ... Boulder, RCCPS is the only global conference exclusively dedicated ...
    ... Biomedical Corporation, a leading developer of whole blood analyzers, ... Sanvita CBGM, LLC, has completed the acquisition of certain ... Inc. , Nova Biomedical is the sole ... Monitoring (CBGM) subsidiary has become the exclusive distributor, of ...
    Cached Medicine Technology:Roche Scientist Recognized for Excellence in Peptide Chemistry 2Roche Scientist Recognized for Excellence in Peptide Chemistry 3Roche Scientist Recognized for Excellence in Peptide Chemistry 4Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
    (Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
    (Date:8/30/2014)... 2014 The federal judge overseeing ... http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. has ... selected for one of the proceeding’s bellwether trials. ... 2014, U.S. District Judge Joseph R. Goodwin of ... Boston Scientific’s contention that a consolidated trial would ...
    (Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
    (Date:8/30/2014)... OK (PRWEB) August 30, 2014 In ... valuable, and increasingly difficult to get. Snoring and sleep ... sleep and breathing stops) robs people and their bed ... daily challenges. Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ...
    (Date:8/30/2014)... Top10BestSEOHosting.com is a well-known review website. Recently, the ... http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the best Windows Hosting supplier ... that Bluehost and Arvixe are excellent companies for ... Top 10 Web Hosting in 2014, is a ... offers rich features and great Windows hosting solutions ...
    Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
    ... available in German . The stomach bacterium ... the development of gastric cancer, the third most common cause of ... Zurich have now identified a mechanism of Helicobacter pylori that damages ... up for malignant transformation. Gastric cancer is one of the ...
    ... Do sexualized lyrics in popular music have an impact on ... Joshua H. West, and Shane Hill from Brigham Young University ... increasing use of sexually explicit lyrics in music. Their ... , provide food for thought for educators whose focus is ...
    ... Academy of Sciences and the Global Medical Excellence Cluster ... College London, will host a two-day scientific conference, ... and Toxicity," that will provide a forum to ... drug discovery. Areas of focus include: how do animal ...
    ... published study by researchers at Columbia University,s Mailman School ... effects on children of a group of ubiquitous chemicals ... that are known to disrupt the endocrine system, and ... toys, to household building materials, to shampoos. Recent ...
    ... News) -- Mild cognitive impairment -- marked by a ... a stronger predictor of Alzheimer,s disease than so-called "biomarkers," ... or levels of certain proteins in cerebrospinal fluid, a ... people with mild cognitive impairment (MCI) who developed Alzheimer,s ...
    ... French . , A major landmark study released ... light on the state of Europe,s mental and neurological health. ... largest health challenge in the 21st century. The study also ... together with the large and increasing number of ,disorders of ...
    Cached Medicine News:Health News:Stomach bacterium damages human DNA 2Health News:Songs about sex - how they affect kids 2Health News:New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery 2Health News:New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Short-Term Memory Loss May Be Best Predictor of Alzheimer's 2Health News:The size and burden of mental disorders in Europe 2Health News:The size and burden of mental disorders in Europe 3
    Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
    Angled 45 degree shafts 8 mm from tip to bend with 5 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
    Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
    Straight shafts with 4 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
    Medicine Products: